Search clinical trials for: Valsartin

Total 483 results

University of Chicago

Completed

Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

Heart Failure

United States
Viatris Inc.

Not yet recruiting

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Bioequivalence Study

Thailand
University of Pennsylvania

Suspended

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Hypertension | Diabetes Mellitus, Type 2 | Pre-diabetic | Elevated Blood Pressure

United States
University Hospital, Grenoble

Recruiting

National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril/Valsartan (ISACC)

Complex Congenital Heart Disease

France
Brigham and Women's Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

Hemodialysis

United States
Novartis Pharmaceuticals

Withdrawn

Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure (LOCATE-HF)

Heart Failure
Dexa Medica Group

Completed

Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg

Healthy

Indonesia
Virginia Commonwealth University

Recruiting

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (TREAT-HF)

Heart Failure | Heart Dysfunction

United States
Unity Health Toronto
Alere, Inc.

Unknown

Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure

Heart Failure

Canada
LanZhou University

Recruiting

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Hypertension

China
International Bio service

Not yet recruiting

Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets

Healthy Volunteer
Silesian Centre for Heart Diseases
Medical Research Agency, Poland

Not yet recruiting

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Heart Failure | Breast Cancer | Breast Diseases | Cardiotoxicity | Molecular Mechanisms of Pharmacological Action | Angiotensin Receptor Antagonists | Neoplasm, Breast | Cardiac Toxicity | Angiotensin II Type 1 Receptor Blockers | Cancer, Therapy-Related | Antihypertensive Agents | Sacubitril/Valsartan | Cancer...

Poland
NHS Greater Glasgow and Clyde
University of Glasgow

Completed

The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI (RECOVER-LV)

Heart Failure

United Kingdom
Novartis Pharmaceuticals

Terminated

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Heart Failure With Preserved Ejection Fraction (HFpEF)

Japan
Mark Ledwidge
The Heartbeat Trust

Active, not recruiting

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation (PARABLE)

Hypertension | Atrial Remodeling | Cardiovascular Morbidity | Myocardial Dysfunction | Atrial Arrhythmia | Left Ventricular Remodeling | Left Ventricular Diastolic Dysfunction | Inflammatory Myopathy | Fibrosis Myocardial

Ireland
Novartis Pharmaceuticals

Completed

Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting (PARASAIL)

Hearth Failure With Reduced Ejection Fraction (HFrEF)

Canada
The Second Affiliated Hospital of Harbin Medical...

Unknown

Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure

CKD
The Young Investigator Group of Cardiovascular...

Completed

The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction (RSVP-AMI)

Acute Myocardial Infarction

Egypt
Novartis
The TIMI Study Group

Completed

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Myocardial Ischemia | Post Acute Coronary Syndrome

Germany, Spain, United States, Belgium, Canada, Czech Republic, Hungary, Netherlands, Poland, Russian Federation, Sweden
Chongqing Medical University

Not yet recruiting

The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF (ARNICFH)

Heart Failure With Preserved Ejection Fraction

China
Jacob Moller
Odense University Hospital; Rigshospitalet, Denmark; Danish Heart Foundation

Recruiting

Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI (ARNiAMI)

Myocardial Infarction | Diastolic Dysfunction

Denmark
Duke University
Novartis Pharmaceuticals

Completed

Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 (PARACOR-19)

Covid19

United States
RenJi Hospital

Unknown

Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD (EARLY-MYO-CTD)

Myocardial Injury | Connective Tissue Diseases

China
Oslo University Hospital

Unknown

Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin

Heart Failure, Systolic

Norway
Novartis Pharmaceuticals

Completed

CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Heart Failure

United States, Italy, Croatia, India, Japan, Poland, Spain, Taiwan, Austria, Korea, Republic of, Germany, Lebanon, Thailand, Canada, Bulgaria, Russian Federation, Turkey, Switzerland, Argentina, Hungary, Portugal, Finland, South Africa and more
University of Zagreb

Active, not recruiting

Sacubitril/Valsartan in Left Ventricular Assist Device Recipients (ENVAD-HF)

Heart Failure

Netherlands, Croatia, Poland, Czechia
Torbjorn Omland
Oslo University Hospital; Novartis; University Hospital of North Norway; Helse... and other collaborators

Active, not recruiting

Prevention of Cardiac Dysfunction During Breast Cancer Therapy (PRADAII)

Heart Failure | Breast Cancer Female

Norway
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction (PERSPECTIVE)

Chronic Heart Failure (CHF)

Spain, Croatia, Taiwan, Germany, Italy, United States, Australia, Netherlands, Switzerland, Belgium, United Kingdom, Bulgaria, Lithuania, Russian Federation, France, Argentina, Korea, Republic of, Poland, Canada, Turkey
Newcastle-upon-Tyne Hospitals NHS Trust
Assistance Publique - Hôpitaux de Paris; Azienda Ospedaliero-Universitaria... and other collaborators

Completed

Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy (SILICOFCM)

Hypertrophic Cardiomyopathy

United Kingdom
Novartis Pharmaceuticals

Completed

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Heart Failure

United States
Clinision

Completed

Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients

Heart Failure NYHA Class II | Heart Failure NYHA Class IV

Pakistan
University of Michigan
Novartis Pharmaceuticals

Withdrawn

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

Hypertension | Metabolic Syndrome

United States
Ziekenhuis Oost-Limburg
Jessa Hospital

Recruiting

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation (PRAISE-MR)

Heart Failure With Preserved Ejection Fraction | Functional Mitral Regurgitation

Belgium
Shenzhen Second People's Hospital

Recruiting

The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

Heart Failure | Hemodialysis Complication | Peritoneal Dialysis Complication

China
Horng Chen

Enrolling by invitation

Enhancing the Natriuretic Peptide System in HFpEF

Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States
Germans Trias i Pujol Hospital

Completed

Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device (ARNIMEMS-HFpEF)

Pulmonary Hypertension

Spain
University Hospital, Montpellier

Completed

Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study (ENTRESTO696)

Chronic Heart Failure | Sleep Apnea Syndrome

France
LG Life Sciences

Completed

Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

Hypertension

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients. (AWAKE-HF)

Heart Failure, Reduced Ejection Fraction

United States
Sun Yat-sen University

Completed

Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients

Renal Function Disorder

China
Novartis

Completed

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Proteinuria | Microalbuminuria

Egypt
Novartis

Completed

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

Diastolic Dysfunction, Symptomatic Heart Failure

Switzerland, Germany
Kumamoto University

Terminated

Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Hypertension

Japan
Novartis

Completed

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

Hypertension

Germany
Novartis

Completed

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

Hypertension

Switzerland
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

Hypertension

Germany, United States
Jikei University School of Medicine

Unknown

A Morbidity-Mortality and Remodeling Study With Valsartan

Hypertension | Ischemic Heart Disease | Congestive Heart Failure

Japan
National Heart Centre Singapore
National Medical Research Council (NMRC), Singapore

Recruiting

Role of ARNi in Ventricular Remodeling in Hypertensive LVH (REVERSE-LVH)

Hypertensive Heart Disease

Singapore
Newcastle University
University of Belgrade; Azienda Ospedaliero-Universitaria Careggi; University... and other collaborators

Completed

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy (SILICOFCM)

Hypertrophic Cardiomyopathy

Germany, Italy, Serbia, United Kingdom
National Institute of Cardiovascular Diseases,...

Completed

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Heart Failure, Systolic

Pakistan

Search clinical trials for: Valsartin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations